<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99304">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02117258</url>
  </required_header>
  <id_info>
    <org_study_id>Z-360-01</org_study_id>
    <nct_id>NCT02117258</nct_id>
  </id_info>
  <brief_title>Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma</brief_title>
  <acronym>ZIPANG</acronym>
  <official_title>Randomized Phase II Study of Gemcitabine Plus Z-360 in Metastatic Pancreatic Adenocarcinoma Compared With Gemcitabine Plus Placebo ( ZIPANG Study )</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zeria Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zeria Pharmaceutical</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <authority>Taiwan : Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the efficacy of GEM plus Z-360 versus GEM
      plus placebo on the overall survival (OS) in subjects with metastatic Pancreatic
      Adenocarcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Approximately 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure</measure>
    <time_frame>Approximately 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Approximately 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters</measure>
    <time_frame>Approximately 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of SAEs and AEs, laboratory test results, vital signs, ECG results and physical examination findings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Day1</time_frame>
    <safety_issue>No</safety_issue>
    <description>To characterize the plasma pK of Z-360 when given in combination with GEM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Approximately 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Benefit Rate</measure>
    <time_frame>Approximately 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Metastatic Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Z-360 60mg+Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Z-360 60 mg will be taken orally, twice daily (BID) after a meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Z-360 120mg+Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Z-360 120 mg will be taken orally, twice daily (BID) after a meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Z-360 240mg+Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Z-360 240 mg will be taken orally, twice daily (BID) after a meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+Gemcitabine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be taken orally, twice daily (BID) after a meal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Z-360</intervention_name>
    <description>Gemcitabine (1,000 mg/m^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while Z-360 (60, 120 or 240 mg) will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.</description>
    <arm_group_label>Z-360 60mg+Gemcitabine</arm_group_label>
    <arm_group_label>Z-360 120mg+Gemcitabine</arm_group_label>
    <arm_group_label>Z-360 240mg+Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Gemcitabine (1,000 mg/m^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while placebo will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.</description>
    <arm_group_label>Placebo+Gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Subjects with histological or cytological evidence of metastatic Pancreatic
             Adenocarcinoma, Measurable disease or non-measurable disease by Response Evaluation
             Criteria in Solid Tumors (RECIST) version criteria

          -  2. Subjects with a life expectancy of at least 12 weeks,

          -  3. Subjects with an Eastern cooperative oncology group performance status (ECOG PS)
             of 0, 1 or 2,

          -  4. Subjects with the following adequate organ functions:

               -  White blood cell count ≥3,000/μL (or absolute neutrophil count ≥1,500/μL) and ≤
                  12,000/μL ,

               -  Platelet count ≥100.0 × 10^9/L,

               -  Hemoglobin ≥9.0 g/dL,

               -  Serum creatinine ≤1.5 × the upper limit normal (ULN),

               -  Total bilirubin ≤2.0 × ULN,

               -  Serum aspartate transaminase levels ≤3.0 × ULN (≤5.0 × ULN in presence of liver
                  metastases), and

               -  Serum alanine aminotransferase levels ≤3.0 × ULN (≤5.0 × ULN in presence of
                  liver metastases).

        Exclusion Criteria:

          -  Subjects received the following previous therapies for Pancreatic Adenocarcinoma:

               -  Surgery within the 4 weeks prior to randomization,

               -  Radiation and chemoradiation within the 12 weeks prior to randomization,

               -  Radiation for pain relief within the 4 weeks prior to randomization,

               -  Gemcitabine used as a neoadjuvant or an adjuvant on surgery within the 24 weeks
                  prior to randomization,

               -  Chemotherapy except GEM used as an adjuvant on surgery within the 4 weeks prior
                  to randomization,

               -  Gemcitabine ≥600 mg/m^2 as sensitizer for chemoradiation,

               -  Gemcitabine &lt;600 mg/m^2 as sensitizer for chemoradiation within the 12 weeks
                  prior to randomization,

               -  Gemcitabine used for systemic chemotherapy, or

               -  Systemic chemotherapies except GEM within the 4 weeks prior to randomization.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zeria Investigator</last_name>
    <phone>+81356447053</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Zeria Investigative sites</name>
      <address>
        <city>Japan</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zeria Investigator</last_name>
      <phone>+81-356447053</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zeria Investigative Sites</name>
      <address>
        <city>Korea</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zeria Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zeria Investigative Sites</name>
      <address>
        <city>Taiwan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zeria Investigator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 26, 2014</lastchanged_date>
  <firstreceived_date>April 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Z-360, Pancreatic cancer, Pancreatic Adenocarcinoma</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
